Anti-HLA-G Purified

Anti-HLA-G Purified
Regulatory status
RUO
Antigen
HLA-G
Clone
MEM-G/9
Format
Purified
Reactivity
Human
Variant
0.1 mg
11-292-C100
In stock
187.00 USD

1.0 mg
11-292-M001
In stock
561.00 USD

0.025 mg
11-292-C025
Delivery 1 week
93.50 USD
Variant
0.1 mg
11-292-C100
In stock
187.00 USD

1.0 mg
11-292-M001
In stock
561.00 USD

0.025 mg
11-292-C025
Delivery 1 week
93.50 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG1
Specificity
The antibody MEM-G/9 reacts with an extracellular epitope on native form of human HLA-G1 on the cell surface as well as with soluble HLA-G5 isoform in its beta2-microglobulin associated form. Reactivity with HLA-G3 was also reported. The antibody MEM-G/9 is standard reagent thoroughly validated during 3rd International Conference on HLA-G (Paris, 2003).
Application details
Flow cytometry: Recommended dilution: 0.3-4 μg/ml; positive control: JEG-3 human choriocarcinoma cell line.
Immunocytochemistry: Recommended dilution: 2-5 μg/ml.
ELISA: The antibody MEM-G/9 has been tested as the capture antibody in a sandwich ELISA for analysis of human HLA-G in combination with antibody B2M-01 or with antibody W6/32. Coating antibody 10 μg/ml, detection antibody (biotin or peroxidase conjugate) 1 μg/ml.
Reactivity
Human
Negative species
Mouse
Immunogen
Recombinant human HLA-G refolded with beta2-microglobulin and peptide.
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Antigen description
Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.
Entrez Gene ID 3135
UniProt ID P17693
11-292_FC_Histogram
Separation of HLA-G trasnfected LCL cells (red-filled) from K562 cells (black-dashed) in flow cytometry analysis (surface staining) stained using anti-human HLA-G (MEM-G/9) purified antibody (concentration in sample 0.3 μg/ml, GAM APC).
11-292 IP
Immunoprecipitation of HLA-G from HLA-G1 transfectants (LCL-HLA-G1) by anti-human HLA-G (MEM-G/9) and protein G. HLA-G was detected by anti-human HLA-G (clone 4H84) and goat anti-mouse HRP in cell lysate (Lane 1) and in the immunoprecipitate (Lane 2).

General references:

Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, Charpentier B, Carosella ED, Rouas-Freiss N. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol. 2003 39(4):587-94.
PubMed
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, LeDanff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 64(3):315-26.
PubMed
Lin A, Yan WH: Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front Immunol. 2018 Sep 27;9:2164.
PubMed
Hunt JS, Langat DK, McIntire RH, Morales PJ: The role of HLA-G in human pregnancy. Reprod Biol Endocrinol. 2006;4 Suppl 1(Suppl 1):S10.
PubMed
Xu HH, Yan WH, Lin A: The role of HLA-G in human papillomavirus infections and cervical carcinogenesis. Front Immunol. 2020 Jun 25;11:1349.
PubMed
Castelli EC, de Almeida BS, Muniz YC, Silva NS, Passos MR, Souza AS, Page AE, Dyble M, Smith D, Aguileta G, Bertranpetit J, Migliano AB, Duarte YA, Scliar MO, Wang J, Passos-Bueno MR, Naslavsky MS, Zatz M, Mendes CT, Donadi EA: HLA-G genetic diversity and evolutive aspects in worldwide populations. Sci Rep. 2021 Nov 29;11(1):23070.
PubMed
Curigliano G, Criscitiello C, Gelao L, Goldhirsch A: Molecular pathways: Human leukocyte antigen G (HLA-G). Clin Cancer Res. 2013 Oct 15;19(20):5564-71.
PubMed

Product specific references:

Zhao L, Teklemariam T, Hantash BM: Reassessment of HLA-G isoform specificity of MEM-G/9 and 4H84 monoclonal antibodies. Tissue Antigens. 2012 Sep;80(3):231-8
PubMed
Fuzzi B, Rizzo R, Criscuoli L, Noci I, Melchiorri L, Scarselli B, Bencini E, Menicucci A, Baricordi OR: HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur J Immunol. 2002 Feb;32(2):311-5.
PubMed
Gonen-Gross T, Achdout H, Arnon TI, Gazit R, Stern N, Horejsí V, Goldman-Wohl D, Yagel S, Mandelboim O: The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J Immunol. 2005 Oct 15;175(8):4866-74.
PubMed
Lopez AS, Alegre E, LeMaoult J, Carosella E, Gonzalez A. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol Immunol. 2006 Jul;43(14):2151-60.
PubMed
Abstracts from the 3rd International Conference on HLA-G. Tissue Antigens 62, 339-357 (2003).
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 Mar;64(3):315-26.
PubMed
Pangault C, Le Friec G, Caulet-Maugendre S, Lena H, Amiot L, Guilloux V, Onno M, Fauchet R: Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Hum Immunol. 2002 Feb;63(2):83-90.
PubMed
Lozano JM, Gonzalez R, Kindelan JM, Rouas-Freiss N, Caballos R, Dausset J, Carosella ED, Pena J: Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. AIDS. 2002 Feb 15;16(3):347-51.
PubMed
Fournel S, Huc X, Aguerre-Girr M, Solier C, Legros M, Praud-Brethenou C, Moussa M, Chaouat G, Berrebi A, Bensussan A, Lenfant F, Le Bouteiller P: Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules. Tissue Antigens. 2000 Jun;55(6):510-8.
PubMed
Morandi F, Ferretti E, Bocca P, Prigione I, Raffaghello L, Pistoia V: A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis. PLoS One. 2010 Jul 23;5(7):e11763.
PubMed
Emadi E, Khoradmehr A, Shams A, Kalantar SM: Appropriate fixative for MEM-G/9 staining of cultured human HLA-G-positive JEG-3 trophoblast tumor cells. Biotech Histochem. 2022 Feb;97(2):136-142.
PubMed
Variant
0.1 mg
11-292-C100
In stock
187.00 USD

1.0 mg
11-292-M001
In stock
561.00 USD

0.025 mg
11-292-C025
Delivery 1 week
93.50 USD
Variant
0.1 mg
11-292-C100
In stock
187.00 USD

1.0 mg
11-292-M001
In stock
561.00 USD

0.025 mg
11-292-C025
Delivery 1 week
93.50 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
0.1 mg
115.50 USD